Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2005-07-05
2005-07-05
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
Reexamination Certificate
active
06914076
ABSTRACT:
The method for the treatment of chronic uremic patients undergoing periodical dialysis is useful for preventing and/or treating carnitine deficiency in patients with end stage renal disease who are undergoing dialysis. The method according to the present invention comprises administering an effective dose of carnitine intravenously into the venous return line after each dialysis session.
REFERENCES:
patent: 4237167 (1980-12-01), Cavaza
patent: 4272549 (1981-06-01), Cavazza
patent: 4602039 (1986-07-01), Cavazza
patent: 6051608 (2000-04-01), Santaniello et al.
patent: 6245378 (2001-06-01), Cavazza
patent: 6335369 (2002-01-01), Cavazza
patent: 6429230 (2002-08-01), Cavazza
patent: 6537976 (2003-03-01), Gupta
patent: 6696493 (2004-02-01), Cavazza
patent: WO 99 07419 (1999-02-01), None
Borum P. R. and Taggart E. M, “Carnitine Nutriture of Dialysis Patients”,J. Am. Diet. Assoc.86:644-647 (1986).
Bazzato G. et al., “Mysthenia-Like Syndrome After D.L—But Not L-Carnitine”Lancet1:1209 (1981).
Thomas, S. et al., “Effects of L-Carnitine on Leukocyte Function and Viability in Hemodialysis Patients: A Double-Blind Randomized Trial”,Am. J. Kidney Dis.,34(4):678-687 (1999).
Elisaf, M. et al., “Effect of L-Carnitine Supplementation on Lipid Parameters in Hemodialysis Patients”,Am. J. Nephrol.18(5):416-421 (1998).
Topalo{hacek over (g)}lu R. et al, “Effect of Carnitine Supplementation on Cardiac Function in Hemodialyzed Children,”Acta Paediatr Jpn40:26-29 (1998).
Vacha, G.M. et al, “L-Carnitin Addition to Dialysis Fluid”,Nephron51:237-242 (1989).
Kavuçu S. et al,“The Effects of L-Carnitine on Respiratory Function Tests in Children Undergoing Chronic Hemodialysis”,Turk. J. Pedia.40(1):79-84 (1998).
Borum P.R. and Taggart E.M., “Carnitine Nutriture of Dialysis Patients”,J. Am. Diet. Assoc.86:644-647 (1986).
Bazzato G. et al, “Myasthenia—Like Syndrom After D.L-But not L Carnitine”, La{tilde over (c)}net 1:1209 (1981).
Ahmad et al, Kidney International, vol. 36, Suppl. 27 (1989), pp. S-243—S-246 Fatty Acid abnormalities in hemodialysis patients: Effect of L-carnitine adminsitration.
Golper et al, Kidney International, vol. 38 (199) pp. 904-911 Multicenter trial of L-carnitine in maintenance hemodialysis patients. I. Carnitine concentrations and lipid effects.
Ahmad et al, Kidney International, vol. 38 (1990), pp. 912-918 Multicenter trial of L-carnitine in maintenance hemodialysis patients. II. Clinical and biochemical effects.
Ahmad et al, “Role of L-Carnitine in Treating Renal Dialysis Patients”, Apr., 1994, Dialysis & Transplantation, pp. 178-181.
Casciani et al, “Beneficial Effects of L-Carntine in Post-Dialysis Syndrome,” Current Therapeutic Research, vol. 32, No. 1, Jul., 1982, pp. 116-127.
Hiatt et al, “Carnitine metabolism during exercise in patients on chronic hemodialysis,” Kidney International, vol. 41 (1992), pp. 1613-1619.
Pons et al, “Primary and Secondary Carnitine Deficiency Syndromes”, Journal of Child Neurology, vol. 10, Supplement No. 2, pp. 2S8-2S24, Nov. 1995.
Labonia, “L-Carnitine Effects on Anemia in Hemodialyzed Patients Treated with Erthropoietin”, American Journal of Kidney Diseases, vol. 26, No. 5 (Nov.), 1995; pp. 757-764.
Matsumura et al, “Correlation between Serum Carnitine Levels and Erythrocyte Osmotic Fragility in Hemodialysis Patients”, Nephron 1996; 72:574-578.
Brass, “Carnitine in Renal Failure”, Nutritional Management of Renal Disease, Kopple & Massury, editors, Williams & Wilkins (1997), pp. 191-201.
“Energy Metabolism: The Role of Carnitine”, An educational supplement to The Journal of Care Management, vol. 3., No. 5, Oct., 1997, pp. 1-12.
Henley III Raymond J.
Nixon & Vanderhye P.C.
Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
LandOfFree
Treating chronic uremic patients undergoing periodical dialysis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treating chronic uremic patients undergoing periodical dialysis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treating chronic uremic patients undergoing periodical dialysis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3396496